Testosterone replacement therapy (TRT) is a generally accepted method treating for aging-related late-onset hypogonadism (LOH). Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research. Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions. We provide advanced analytical research solutions while offering information-enriched research studies. Organizations are increasingly emphasizing data-driven decision-making, sustainability-driven initiatives, and strong compliance frameworks to effectively respond to shifting market dynamics and evolving regulatory expectations. We believe the evidence presented in this study support the position that the importance of TD in health care and the benefits of TTh in these men is under-recognized and underappreciated. Men with chronically low testosterone have weaker muscle mass and strength, which contribute to reduced lung capacity.46 This raises the question whether TD is a risk factor for severe COVID-19 illness. Still, the meta-analysis showed robust effects of TTh on reduction in fat mass, increase in lean mass, improved fasting glucose and insulin resistance.31 In one meta-analysis, one third of the studies had a duration of 3 months or less. Although more studies are needed to better understand this protective and therapeutic relationship between TTh and prostate cancer, it is now evident that prostate cancer can no longer be considered a risk of TTh. Although for decades it was believed that TTh increased the risk of developing prostate cancer, we have now entered an era where TTh is being used in clinical trials for potential therapeutic and protective effects. In addition, patients receiving BAT reported significantly greater improvement in quality of life, especially fatigue and sexual function. Another important nuance is that women are not simply treated like men at a lower dose. But the evidence supporting those broader uses is limited or inconsistent. Testosterone is often marketed to women as an answer for fatigue, low motivation, reduced exercise performance, poor body composition, hot flashes, and vague hormone imbalance. Some women do report wider subjective benefits such as improved motivation or overall well-being. That is a remarkably important point because it draws a line between evidence-based care and wishful extrapolation (Davis et al., Journal of Sexual Medicine, 2019). They also reported that the changes in PV after 12 months were likely related to aging rather than testosterone therapy. However, it remains unclear whether the patients were taking medications to treat LUTS during the study period. Only the subgroup analysis of RCTs published after 2010 showed an improvement in Qmax in TRT group. In addition, bilaterally oophorectomized women experience a sharp drop in T level of up to 50% after surgery (8). No significant effect was noted on anthropometric measures and bone density. This section collects any data citations, data availability statements, or supplementary materials included in this article. The original contributions presented in the study are included in the article/Supplementary Material. But there are no significant difference in changes of IPSS, PSA, PV, Qmax and PVR regardless of the administration method or duration of treatment among men in TRT group versus those in placebo group. However, it is essential to acknowledge certain limitations in our study.
